Mölnlycke & Ondine Team Up for Infection Control Innovation
Mölnlycke Health Care is thrilled to announce a strategic partnership with Ondine Biomedical Inc. Together, they aim to boost infection control measures across key regions, particularly in the UK, EU, and Middle East. This collaboration focuses on distributing Ondine's pioneering Steriwave nasal decolonisation technology, a significant step forward in tackling healthcare-associated infections (HAIs) while avoiding antibiotic resistance.
A New Chapter in Decolonisation Technology
Steriwave is a non-antibiotic, light-activated nasal treatment that has shown clinical results in greatly reducing harmful pathogens in the nasal passages. This is especially important since these pathogens can lead to serious infections after surgery, which can affect patient safety and hospital resource management. With its extensive distribution network spanning over 100 countries, Mölnlycke is well-positioned to promote the use of Steriwave, particularly in hospitals where HAIs continue to be a major issue.
Addressing the Challenge of Antimicrobial Resistance
As antimicrobial resistance (AMR) grows into a formidable global health challenge, the introduction of Steriwave offers a hopeful alternative. The therapy operates quickly, eliminating drug-resistant pathogens in a brief 5-minute treatment session. Research shows that users of Steriwave generally report strong compliance, indicating that both staff and patients understand the importance of efficient decolonisation strategies.
Market Impact and Goals for Expansion
The UK healthcare system presents significant opportunities, particularly within the National Health Service (NHS). Mölnlycke plans to start distributing Steriwave in the UK by Q4 2024, with intentions to expand into the broader EU and Middle Eastern markets by 2025. This partnership aims to utilize Mölnlycke's vast industry presence to enhance the global reach of Steriwave, ultimately improving healthcare practices around the world.
Improving Surgical Outcomes
With over 3 million major surgeries taking place each year in the UK and around 200,000 admissions to ICUs, incorporating Steriwave therapy could significantly enhance surgical outcomes. Mölnlycke is dedicated to maintaining standards that bolster patient care and safety, underscoring their commitment to healthcare innovation.
Insights from Leadership and Ongoing Commitment
Lina Karlsson, Executive Vice President of Antiseptics at Mölnlycke, expressed her enthusiasm for this partnership, saying, "Mölnlycke's purpose is to revolutionise care for people and the planet. Adopting Steriwave as part of our infection control strategy will positively impact millions of lives. Our mission is to advance safe surgical practices and combat HAIs through effective decolonisation methods."
Carolyn Cross, CEO of Ondine Biomedical, shared these sentiments, emphasizing the alignment between their organizations' goals. "We aim to reshape the future of infection control, and with Mölnlycke’s extensive reach and vision, we’re on the path to making a significant impact against HAIs and AMR globally."
Taking Steps Against HAIs
Healthcare-associated infections represent a major concern, straining health budgets and leading to unnecessary patient deaths and prolonged hospital stays. The UK government is increasingly focused on initiatives aimed at reducing these infections, highlighting the necessity for effective solutions like Steriwave. Recommendations for nasal decolonisation found in WHO guidelines and SHEA protocols further bolster the need for these advanced technologies to prevent infections and improve patient care.
Frequently Asked Questions
What is the goal of the Mölnlycke and Ondine partnership?
The partnership aims to distribute Ondine's Steriwave nasal decolonisation technology, targeting healthcare-associated infections and antimicrobial resistance.
How does Steriwave function?
Steriwave employs light-activated technology to eliminate pathogens found in the nasal passages, thereby reducing the risk of infections during surgical procedures.
When will Steriwave be introduced in the UK?
The distribution of Steriwave is scheduled to commence in Q4 2024, with expansion plans into the EU and Middle Eastern markets by 2025.
Why is nasal decolonisation essential?
Nasal decolonisation plays a crucial role in preventing infections that can delay recovery and increase hospitalization costs related to surgical interventions.
What commitment does Mölnlycke have towards infection control?
Mölnlycke is focused on improving patient care through innovative infection control measures, contributing to safer healthcare environments globally.
